Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 900,195 | 828,568 | 841,661 | 860,546 | 836,549 |
| Cost of Goods | 357,224 | 343,641 | 335,035 | 346,514 | 337,796 |
| Gross Profit | 542,971 | 484,927 | 506,626 | 514,032 | 498,753 |
| Operating Expenses | 262,796 | 259,041 | 261,833 | 335,480 | 251,205 |
| Operating Income | 280,399 | 226,527 | 244,828 | 179,066 | 248,344 |
| Interest Expense | 13,127 | 13,547 | 10,998 | 8,317 | 6,996 |
| Other Income | 416 | 235 | 353 | 334 | 143 |
| Pre-tax Income | 267,688 | 213,215 | 234,183 | 171,083 | 241,491 |
| Income Tax | 53,634 | 41,008 | 53,245 | 39,104 | 47,526 |
| Net Income Continuous | 214,054 | 172,207 | 180,938 | 131,979 | 193,965 |
| Net Income | $214,054 | $172,207 | $180,938 | $131,979 | $193,965 |
| EPS Basic Total Ops | 2.58 | 2.08 | 2.17 | 1.57 | 2.30 |
| EPS Basic Continuous Ops | 2.58 | 2.08 | 2.17 | 1.57 | 2.30 |
| EPS Diluted Total Ops | 2.55 | 2.05 | 2.15 | 1.56 | 2.27 |
| EPS Diluted Continuous Ops | 2.55 | 2.05 | 2.15 | 1.56 | 2.27 |
| EBITDA(a) | $308,730 | $255,247 | $273,375 | $207,188 | $274,855 |